Full Press Release Details
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP)
Immutep to Present Interim Results from TACTI-mel Clinical Trial in Global Webcast
Chief Medical Officer Dr. Frederic Triebel to Present at the
3rd Annual Advances in Immuno-Oncology Congress
SYDNEY, AUSTRALIA May 17, 2018 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or
the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, advises that its Chief Medical Officer and Chief Scientific Officer, Dr. Fr d ric Triebel, will
present interim results from the three initial patient cohorts of its ongoing TACTI-mel Phase I clinical trial in a global webcast and Q&A. The webcast will also include an update on the Company s clinical immuno-oncology combination
Dr. Triebel will also present a subset of these interim results at the 3rd Annual Advances in Immuno-Oncology Congress, on
25 May 2018 in London, UK. The presentation, titled Two ACTIve Immunotherapies in melanoma (TACTI-mel): results of a phase I trial with metastatic melanoma patients treated with a soluble LAG-3
receptor (LAG-3Ig or eftilagimod alpha) as an antigen presenting (APC) activator combined with pembrolizumab will be released to the market to coincide with the event and made available on the
Immutep s current lead product is eftilagimod alpha ( efti or IMP321 ), a potential first-in-class major histocompatibility complex class II ( MHC II ) agonist and antigen presenting cell ( APC ) activator. Efti is a soluble LAG-3Ig fusion protein based on the LAG-3 immune control mechanism. This mechanism plays a vital role in the regulation of the T cell immune response. Efti, unlike blocking
antibodies, is unique as it uses LAG-3 itself as a tool to activate the immune system via MHC II molecules.
TACTI-mel Phase I clinical trial is a multi-center, open-label clinical trial evaluating the combination of efti with pembrolizumab (KEYTRUDA ) for unresectable or metastatic melanoma. As
previously disclosed, interim results from the first three cohorts was expected in H1 2018. The trial remains ongoing, following its expansion by an additional cohort, with results from this additional cohort expected in H2 2018.
Investor Webcast Details
The webcast will be hosted by
Dr. Triebel, Marc Voigt, CEO and Christian Mueller, Director of Clinical Development.
Register: Interested investors can register via a link to the webcast on the Company s
website at Clinical Results of Ongoing Melanoma Study and Update on Eftilagimod Alpha Clinical Development Strategy or via the following link.
A replay of the webcast will also be available at www.immutep.com from the day after the event.
About the TACTI-mel clinical trial
The ongoing TACTI-mel (Two ACTive Immunotherapies in melanoma) Phase I clinical trial is a multi-center, open-label, dosing
escalating (1, 6 or 30 mg of eftilagimod alpha or efti ) study evaluating the combination of efti with pembrolizumab for 6 months, starting at treatment cycle 5 in unresectable or metastatic melanoma patients that have had either a
suboptimal response or had disease progression with pembrolizumab monotherapy (clinicaltrials.gov identifier NCT 02676869). The initial study consists of three cohorts of six patients.
In February 2018, Immutep expanded the TACTI-mel study by an additional cohort of 6 patients at 30 mg of efti in combination with pembrolizumab starting at
cycle 1 and with a treatment duration of 12 months. As announced on March 22, 2018, the first patient from this additional cohort has received their first dose.
Immutep is a globally active biotechnology
company that is a leader in the development of immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for
patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
Immutep s current lead product is eftilagimod alpha ( efti or IMP321 ), a soluble LAG-3Ig
fusion protein based on the LAG-3 immune control mechanism. This mechanism plays a vital role in the regulation of the T cell immune response. Efti is currently in a Phase IIb clinical trial as a
chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT 02614833) and a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT 02676869). Additional LAG-three products, including antibodies, for immune response modulation in autoimmunity and cancer are being developed by Immutep s large pharmaceutical partners. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.
For the latest company presentation slides, please visit
For the latest video update on Immutep, please visit the Video section of the
Further information can be found on the Company s website www.immutep.com or by contacting:
Jay Campbell, Vice President of Business
Development and Investor Relations, Immutep Limited
+1 (917) 860-9404; jay.campbell@immutep.com
Australian Investors/Media:
Matthew Gregorowski,
+61 2 8234 0105; mgregorowski@citadelmagnus.com
Sharon Golubchik, Antenna Group
+1 (201) 465-8008; sharon@antennagroup.com